Short Term Topical Tetracaine is Highly Efficacious for the Treatment of Pain Caused by Corneal Abrasions: A Double-blind, Randomized Clinical Trial

Ruby Hoang, DO PGY-IV

Kelly Painter, MD Mark Keuchel, DO Charles Bogie, MD Stacia Shipman, DO INTEGRIS Southwest Medical Center Department of Emergency Medicine 4401 S. Western Oklahoma City, OK 73109

ABSTRACT

Study Objective: The objective of this study was to show that patients with corneal abrasions would experience more pain relief with short term topical tetracaine than placebo.

Methods: The study was a prospective, double-blind, randomized trial of tetracaine versus placebo set in the emergency department (ED). A total of 118 adults who presented with uncomplicated corneal abrasions were included and randomized. The intervention was either topical tetracaine or placebo applied every 30 minutes as needed for 24 hours. The primary outcome was the overall numerical rating scale (NRS) pain score measured at the 24 to 48-hour ED follow-up examination.

Results: 111 patients were included in the final analysis, 56 in the tetracaine group and 55 in the placebo group. At the 24 to 48-hour follow-up, the overall NRS pain score after use of the study drops was significantly lower in the tetracaine group (1) versus placebo group (8) (Δ 7; 95% CI 6,8). Patients in the tetracaine group used less hydrocodone than those in the placebo group. The complication rates between the 2 groups were similar.

Conclusions: Short term topical tetracaine is an efficacious analgesic for acute corneal abrasions, is associated with less hydrocodone use when compared to placebo, and was found to be safe in this sample.



Short Term Topical Tetracaine is Highly Efficacious for the Treatment of Pain Caused by Corneal Abrasions: A Double-blind, Randomized Clinical Trial

Ruby Hoang, DO, Stacia Shipman, DO, Kelly Painter, MD, Mark Keuchel, DO, Charles Bogie, MD

Background

- Corneal abrasions are common Emergency Department complaints.
- Topical anesthetic drops are routinely used as diagnostic therapy but discouraged for outpatient management due reports of rare complications.
- The objective of this study was to compare the

Methods

- Prospective, randomized, double-blind, placebocontrolled trial.
- Approved by IRB and registered with ClinicalTrials.gov.
- Data collected from Jan 2015 Sept 2017 in an urban community ED with 86,000 visits/year.
- Patients were randomized to tetracaine or placebo groups using numbered, sealed opaque envelopes.
- Each envelope contained an antibiotic ophthalmic solution (Polytrim) and either tetracaine or placebo labeled as "study drops."
- Patients also received hydrocodone/APAP 7.5/325 mg #12 for breakthrough pain and asked record amount of hydrocodone taken.
- \bullet
- The secondary outcome was the number of hydrocodone
- Patient were asked to follow up with study ophthalmologist after one week.
- Electronic medical record searched and follow up via telephone.



Integris Southwest Medical Center, Oklahoma City, Oklahoma



